Selecting an Appropriate Experimental Animal Model for Cholangiocarcinoma Research

Overview

Journal J Clin Transl Hepatol

Specialty Gastroenterology

Date 2022 Sep 5

PMID 36062286

Authors

Man Li

Xueli Zhou

Wei Wang

Baoan Ji

Yu Shao

Qianyu Du

Jinghao Yao

Yan Yang

Affiliations

Soon will be listed here.

Abstract

Cholangiocarcinoma (CCA) is a highly aggressive biliary tree malignancy with intrahepatic and extra-hepatic subtypes that differ in molecular pathogeneses, epidemiology, clinical manifestations, treatment, and prognosis. The overall prognosis and patient survival remains poor because of lack of early diagnosis and effective treatments. Preclinical studies have become increasingly paramount as they are helpful not only for the study of the fundamental molecular mechanisms of CCA but also for developing novel and effective therapeutic approaches of this fatal cancer. Recent advancements in cell and molecular biology have made it possible to mimic the pathogenicity of human CCA in chemical-mechanical, infection-induced inflammatory, implantation, and genetically engineered animal models. This review is intended to help investigators understand the particular strengths and weaknesses of the currently used animal models of human CCA and their related modeling techniques to aid in the selection of the one that is the best for their research needs.

Citing Articles

Metformin dampens the progression of cholangiofibrosis induced by thioacetamide using deep learning.

Li C, Deng Y, Pan Y, Liao X, Xie H, Xue X Heliyon. 2024; 10(18):e37347.

PMID: 39309781 PMC: 11416239. DOI: 10.1016/j.heliyon.2024.e37347.

Oncogenic plasmid DNA and liver injury agent dictates liver cancer development in a mouse model.

Chiu V, Yee C, Main N, Stevanovski I, Watt M, Wilson T Clin Sci (Lond). 2024; 138(19):1227-1248.

PMID: 39254423 PMC: 11427747. DOI: 10.1042/CS20240560.

Characterization of a Syngeneic Orthotopic Model of Cholangiocarcinoma by [F]FDG-PET/MRI.

Zachhuber L, Filip T, Mozayani B, Lobsch M, Scheiner S, Vician P Cancers (Basel). 2024; 16(14).

PMID: 39061229 PMC: 11275149. DOI: 10.3390/cancers16142591.

Establishment and characterization of the PDAC-X3 cell line: a novel Chinese-origin pancreatic ductal adenocarcinoma cell line.

Chai C, Tang H, Miao X, Su Y, Li L, Yu C Hum Cell. 2024; 37(5):1578-1592.

PMID: 39012569 DOI: 10.1007/s13577-024-01100-y.

Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line, ICC-X2.

Xu H, Chai C, Tang H, Su Y, Yu C, Li L World J Oncol. 2024; 15(1):114-125.

PMID: 38274721 PMC: 10807924. DOI: 10.14740/wjon1757.

References

Farazi P, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho R . Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 2006; 66(13):6622-7. DOI: 10.1158/0008-5472.CAN-05-4609. View

Chung J, Hong S, Choi B, Cho H, Yu E, Hewitt S . The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res. 2009; 15(2):660-7. PMC: 7556734. DOI: 10.1158/1078-0432.CCR-08-1084. View

Maeda S, Hikiba Y, Fujiwara H, Ikenoue T, Sue S, Sugimori M . NAFLD exacerbates cholangitis and promotes cholangiocellular carcinoma in mice. Cancer Sci. 2021; 112(4):1471-1480. PMC: 8019203. DOI: 10.1111/cas.14828. View

Kang Y, Kim W, Jang J . Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol. 2002; 33(9):877-83. DOI: 10.1053/hupa.2002.127444. View

Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M . Genomic spectra of biliary tract cancer. Nat Genet. 2015; 47(9):1003-10. DOI: 10.1038/ng.3375. View

Yeh C, Maitra A, Lee K, Jan Y, Chen M . Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis. 2003; 25(4):631-6. DOI: 10.1093/carcin/bgh037. View

Ilyas S, Yamada D, Hirsova P, Bronk S, Werneburg N, Krishnan A . A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma. J Biol Chem. 2016; 291(15):8031-47. PMC: 4825008. DOI: 10.1074/jbc.M115.698472. View

Sirica A, Zhang Z, Lai G, Asano T, Shen X, Ward D . A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology. 2007; 47(4):1178-90. DOI: 10.1002/hep.22088. View

Hernandez M, Bergquist J, Leiting J, Ivanics T, Yang L, Smoot R . Patient-Derived Xenografts Can Be Reliably Generated from Patient Clinical Biopsy Specimens. J Gastrointest Surg. 2019; 23(4):818-824. DOI: 10.1007/s11605-019-04109-z. View

10.

Lozano E, Sanchez-Vicente L, Monte M, Herraez E, Briz O, Banales J . Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. Mol Cancer Res. 2013; 12(1):91-100. DOI: 10.1158/1541-7786.MCR-13-0503. View

11.

Fan B, Malato Y, Calvisi D, Naqvi S, Razumilava N, Ribback S . Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012; 122(8):2911-5. PMC: 3408746. DOI: 10.1172/JCI63212. View

12.

Song C, Li Y, Mou H, Moore J, Park A, Pomyen Y . Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. Gastroenterology. 2016; 152(5):1161-1173.e1. PMC: 6204228. DOI: 10.1053/j.gastro.2016.12.002. View

13.

Nakagawa H, Suzuki N, Hirata Y, Hikiba Y, Hayakawa Y, Kinoshita H . Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands. Proc Natl Acad Sci U S A. 2017; 114(19):E3806-E3815. PMC: 5441746. DOI: 10.1073/pnas.1619416114. View

14.

Mohr R, Ozdirik B, Knorr J, Wree A, Demir M, Tacke F . In Vivo Models for Cholangiocarcinoma-What Can We Learn for Human Disease?. Int J Mol Sci. 2020; 21(14). PMC: 7404171. DOI: 10.3390/ijms21144993. View

15.

Al-Bader A, Mathew T, Abul H, Al-Sayer H, Singal P, Dashti H . Cholangiocarcinoma and liver cirrhosis in relation to changes due to thioacetamide. Mol Cell Biochem. 2000; 208(1-2):1-10. DOI: 10.1023/a:1007082515548. View

16.

Zou S, Li J, Zhou H, Frech C, Jiang X, Chu J . Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun. 2014; 5:5696. DOI: 10.1038/ncomms6696. View

17.

Bridgewater J, Galle P, Khan S, Llovet J, Park J, Patel T . Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014; 60(6):1268-89. DOI: 10.1016/j.jhep.2014.01.021. View

18.

Burka L, Washburn K, Irwin R . Disposition of [14C]furan in the male F344 rat. J Toxicol Environ Health. 1991; 34(2):245-57. DOI: 10.1080/15287399109531564. View

19.

Pirenne S, Lemaigre F . Genetically engineered animal models of biliary tract cancers. Curr Opin Gastroenterol. 2019; 36(2):90-98. DOI: 10.1097/MOG.0000000000000610. View

20.

Song X, Xu H, Wang P, Wang J, Affo S, Wang H . Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation. J Hepatol. 2021; 75(4):888-899. PMC: 8453055. DOI: 10.1016/j.jhep.2021.05.018. View